Suresh De Silva

Suresh de Silva, PhD

Chief Scientific Officer, GADLEN Platform

Suresh has served as our Chief Scientific Officer of the GADLEN technology platform since January, 2023. He Previously served as Vice President of Product Development from 2018-2022 and as our Executive Director of Research and Development from 2017-2018. Suresh joined Shattuck in 2017 and is one of the scientific co-inventors of the ARC technology platform and co-led the preclinical development of SL-279252 and SL-172154. Prior to joining Shattuck, Suresh served as the Director of Research and Development at Heat Biologics, Inc. in Durham, NC, where he led external research collaborations and co-developed the ComPact cell-based vaccine platform. Suresh’s research experience spans the fields of gene therapy, infectious disease (HIV) and cancer immunotherapy where he has co-authored numerous publications in lead journals such as Cancer Immunology Research, Nature Medicine, Human Gene Therapy, and the Journal of Biological Chemistry. Suresh has also co-authored several successful federal grant applications, including two R01’s awarded from the National Institute of Allergy and Infectious Diseases (NIAID) and an R21 that was received from the National Cancer Institute (NCI). Suresh received his M.S. and Ph.D. from the University of Rochester, NY, and subsequently completed a successful post-doctoral fellowship at The Ohio State University, where he was a recipient of a Staff Career Development Grant from their College of Veterinary Medicine.

ct sl here 5: